EGFR and diabetes mellitus: Further, the fact that PAMAM dendrimers can either stimulate or inhibit EGFR phosphorylation in vitro and in vivo might lead to their use as novel modulators of EGFR activity and signaling that could offer novel opportunities for therapeutic intervention especially in diabetes-induced end organ pathologies.